Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma: a Prospective, Phase 2 Study

NCT02360501 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT02360501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02360501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma: a Prospective, Phase 2 Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
April 30, 2016
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal neoplasms